Akebia Therapeutics (AKBA) Operating Leases (2019 - 2025)
Historic Operating Leases for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $4.9 million.
- Akebia Therapeutics' Operating Leases fell 5173.09% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year decrease of 5173.09%. This contributed to the annual value of $3.5 million for FY2024, which is 6035.54% down from last year.
- According to the latest figures from Q3 2025, Akebia Therapeutics' Operating Leases is $4.9 million, which was down 5173.09% from $6.3 million recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Operating Leases ranged from a high of $37.7 million in Q1 2022 and a low of $3.5 million during Q4 2024
- Its 5-year average for Operating Leases is $20.2 million, with a median of $16.2 million in 2023.
- Per our database at Business Quant, Akebia Therapeutics' Operating Leases skyrocketed by 3688.72% in 2021 and then plummeted by 6910.67% in 2023.
- Akebia Therapeutics' Operating Leases (Quarter) stood at $33.7 million in 2021, then decreased by 14.07% to $29.0 million in 2022, then plummeted by 69.11% to $8.9 million in 2023, then crashed by 60.36% to $3.5 million in 2024, then surged by 39.16% to $4.9 million in 2025.
- Its Operating Leases stands at $4.9 million for Q3 2025, versus $6.3 million for Q2 2025 and $7.6 million for Q1 2025.